Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Vigonvita Life Sciences Co., Ltd.
蘇州旺山旺水生物醫藥股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2630)

VOLUNTARY ANNOUNCEMENT
NOTICE ON VOLUNTARY EXTENSION OF LOCK-UP PERIOD BY SHAREHOLDERS

This announcement is made by the board (the "**Board**") of directors (the "**Director(s)**") of Vigonvita Life Sciences Co., Ltd. (蘇州旺山旺水生物醫藥股份有限公司) (the "**Company**") on a voluntary basis.

References are made to the prospectus of the Company dated October 28, 2025 (the "**Prospectus**") and the announcement of final offer price and allotment results of the Company dated November 5, 2025 (the "**Allotment Results Announcement**"), in relation to, among other things, the Shares held by all Pre-IPO Investors, including the controlling shareholders of the Company, being subject to a lock-up period which will expire on November 5, 2026 (the "**Original Lock-up Period**"). Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the Prospectus and the Allotment Results Announcement.

Recently, the Company has received notifications from all the Pre-IPO Investors, including the controlling shareholders, pursuant to which, based on their high recognition of the value of the Company's research and development pipeline, the commercialization prospects of the approved drugs, and the core management team, each of them has undertaken that, during the subsequent extended lock-up period of 7 months or 4 months from the expiry date of the Original Lock-up Period (the "**Lock-up Period Extension**"), they will not in any way dispose of the Shares of the Company held by them respectively.

The Company believes that the Lock-up Period Extension demonstrates the confidence of the aforesaid Shareholders in the future prospects and long-term value of the Company.

The aforesaid Shareholders will also continue to review the Company's performance and may consider further extending the lock-up period based on the Company's business development.

The specific shareholding information of the aforementioned Shareholders and details of the extended lock-up arrangements are as follows:

(i) Dr. Shen Jingshan (沈敬山), a controlling shareholder of the Company (holding 82,461,110 Shares), and his spouse, Ms. Jin Jie (金潔) (holding 2,272,478 Shares), have each undertaken that they will not in any way dispose of the Shares of the Company held by them from the expiry date of the Original Lock-up Period up to and including June 6, 2027;

(ii) the Shareholders of the Company, Dr. Tian Guanghui (田廣輝) (holding 14,316,611 Shares), Ms. Jin Qing (金青) (holding 5,517,145 Shares), Dr. Hu Tianwen (胡天文) (holding 681,743 Shares), Dr. Wang Zhiqiang (王志強) (holding 397,683 Shares), Ms. Guo Ting (郭婷) (holding 397,683 Shares), Ms. Yao Zheng (藥箏) (holding 397,683 Shares), Dr. Zheng Wei (鄭偉) (holding 340,872 Shares), Dr. Yang Rulei (楊汝磊) (holding 227,248 Shares), Mr. Li Jian (李建) (holding 170,436 Shares), and the employee incentive platform Suzhou Hesheng Enterprise Management Consulting Partnership Enterprise (Limited Partnership) (蘇州合升企業管理諮詢合夥企業(有限合夥)) (holding 6,783,346 Shares), have each undertaken that they will not in any way dispose of the Shares of the Company held by them from the expiry date of the Original Lock-up Period up to and including March 6, 2027; and

(iii) the Shareholders of the Company, Ganzhou Yufei Shanshui Equity Investment Partnership Enterprise (Limited Partnership) (贛州予飛杉水股權投資合夥企業(有限合夥)) (holding 7,174,758 Shares), Gongqingcheng Zhongcai Qihu Phase II Internet Industry Investment Center (Limited Partnership) (共青城中財奇虎二期互聯網產業投資中心(有限合夥)) (holding 4,370,157 Shares), Suzhou Xieyao Kexin Venture Capital Partnership Enterprise (Limited Partnership) (蘇州協耀科新創業投資合夥企業(有限合夥)) (holding 4,370,157 Shares), Jiaxing Yuhan Equity Investment Partnership Enterprise (Limited Partnership) (嘉興譽瀚股權投資合夥企業(有限合夥)) (holding 3,563,519 Shares), Qingdao Bei'an Industrial Investment Holding Co., Ltd. (青島北岸產業投資控股有限公司) (holding 3,401,354 Shares), Shenzhen Ruikang Yuhong Win Win Investment Partnership (Limited Partnership) (深圳市銳康宇宏共贏投資合夥企業(有限合夥)) (holding 1,429,197 Shares), Hainan Junshi Phase I Equity Investment Fund Partnership Enterprise (Limited Partnership) (海南君實一期股權投資基金合夥企業(有限合夥)) (holding 1,720,925 Shares), Hangzhou Hemeng Medical Intelligence Equity Investment Partnership Enterprise (Limited Partnership) (杭州和盟醫智股權投資合夥企業(有限合夥)) (holding 1,376,758 Shares), Qingdao Wangde Venture Capital Partnership Enterprise (Limited Partnership) (青島旺德創業投資合夥企業(有限合夥)) (holding 1,241,500 Shares), Suzhou Meilingge Business Consulting Partnership Enterprise (Limited Partnership) (蘇州美靈格商務諮詢合夥企業(有限合夥)) (holding 1,092,539 Shares), Fuzhou Yide Equity Investment Partnership Enterprise (Limited Partnership) (福州宜德股權投資合夥企業(有限合夥)) (holding 1,032,546 Shares), Suzhou Junding Changwang Entrepreneurship Investment Center (Limited Partnership) (蘇州君鼎長旺創業投資中心(有限合夥)) (holding 1,032,546 Shares), Suzhou Xieyao Kesheng Entrepreneurship Investment Partnership Enterprise (Limited Partnership) (蘇州協耀科盛創業投資合夥企業(有限合夥)) (holding 1,032,546 Shares), Suzhou Industrial Investment Innovation and Entrepreneurship Investment Partnership Enterprise (Limited Partnership) (蘇州產投創新創業投資合夥企業(有限合夥)) (holding 876,904 Shares), Hubei Jiuzhou Ketou Health Venture Capital Fund Partnership (Limited Partnership) (湖北九州科投健康創業投資基金合夥企業(有限合夥)) (holding 869,116 Shares), Fuzhou Xindui Investment Partnership Enterprise (Limited Partnership) (福州鑫兌投資合夥企業(有限合夥)) (holding 688,379 Shares), and Hubei Chuangxin Tongxiang Enterprise Management Partnership (Limited Partnership) (湖北創新同享企業管理合夥企業(有限合夥)) (holding 63,061 Shares), have each undertaken that they will not in any way dispose of the Shares of the Company held by them from the expiry date of the Original Lock-up Period up to and including March 6, 2027.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company's Shares.

By order of the Board
Vigonvita Life Sciences Co., Ltd.
Dr. Tian Guanghui
Chairman of the Board, Executive Director,
Chief Executive Officer and General Manager

Hong Kong, October 30, 2026

As at the date of this announcement, the Board comprises Dr. Tian Guanghui and Dr. Hu Tianwen as executive Directors, Mr. Liu Haoxuan as non-executive Director, and Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi as independent non-executive Directors.